Isoquinolines as inhibitors of HPK1
US11566003B2 · kind B2 · utility
0Cited by
5References
31Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 6, 2020 |
| Grant date | Jan 31, 2023 |
| Priority date | — |
| Expiry date | Aug 5, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D519/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.